Vertex Pharmaceuticals shares are trading higher after the company announced results from Phase 2 study of VX-147 in APOL1-mediated focal segmental glomerulosclerosis. The company said ‘treatment with VX-147 led to a statistically significant, substantial and clinically meaningful mean reduction in proteinuria of 47.6%.’